Pulsatile Release
Pulsatile Release - Related Videos
10:02
Characterization of the Isolated, Ventilated, and Instrumented Mouse Lung Perfused with Pulsatile Flow
0 Views •
Cited by 12 •
2011
The following protocol outlines the process of isolating, ventilating and instrumenting mouse lungs to measure steady or pulsatile pulmonary vascular pressure-flow relationships in order to quantify the effects of blood flow, airflow, airway changes and vascular changes on right ventricular afterload.
11:22
Engineering Biological-Based Vascular Grafts Using a Pulsatile Bioreactor
0 Views •
Cited by 31 •
2011
Our group has developed a bioreactor culture system that mimics the physiological pulsatile stresses of the cardiovascular system to regenerate implantable small-diameter vascular grafts.
07:44
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
0 Views •
Cited by 2 •
2023
This method describes the encapsulation of the rabies antigen into biodegradable polymeric microparticles with structural and material properties that enable pulsatile release after a predetermined delay. Enzyme-linked immunosorbent assay (ELISA) assessment of the antigen retrieved from the particle core confirms the presence of intact trimeric rabies virus glycoprotein through particle fabrication.
01:28
Energy-releasing Steps of Glycolysis
0 Views •
2019
Glycolysis is divided into two phases based on whether energy is utilized or released. While the first phase consumes ATP, the second phase produces energy in the form of ATP and NADH. The energy is released over a sequence of reactions that turns G3P into pyruvate. The energy-releasing phase—steps 6-10 of glycolysis—occurs twice, once for each of the two 3-carbon sugars produced during steps 1-5 of the first phase. The first energy-releasing step—the 6th step of glycolysis —consists of two...
01:25
Inhibitors Of Virion Release
0 Views •
2026
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
FAQs
These structures temporarily block diffusion, preventing the therapeutic agent from leaving the system immediately. A coating or barrier is designed to remain intact during a lag period and then be removed or degraded, allowing the stored agent to diffuse outward. Repeating barriers or layers can produce multiple release events, making timing a controllable design variable in bioengineered delivery systems.
Reservoir devices separate the therapeutic agent from the surrounding environment until a barrier no longer prevents transport. This arrangement allows the formulation to hold an agent and delay its movement rather than releasing it continuously from the beginning. In implant design, reservoir-based architectures can therefore support programmed dose timing when distinct treatment events are needed.
Stimuli-responsive materials delay release until a physical or chemical trigger changes the material or removes its barrier function. The trigger provides an additional timing mechanism beyond passive diffusion, allowing release to respond to a defined condition. Such materials are relevant when a bioengineered system must coordinate drug availability with changing biological or treatment-related circumstances.
Constant-rate delivery aims to provide an agent continuously, whereas pulsatile release separates administration into timed bursts with intervening delays. This difference matters when treatment needs vary over time, because a burst-based schedule can reduce unnecessary exposure between doses and better align delivery with biological rhythms, disease cycles, or other time-dependent requirements.
Development begins by matching the desired timing pattern to an appropriate architecture, such as layered coatings, degradable barriers, reservoir devices, or stimuli-responsive materials. Designers then use the selected structure to establish the lag before each release event and the separation between bursts. The resulting system is evaluated by whether its timing supports the intended therapeutic schedule.
Applications include drug-delivery systems, implant design, and responsive biomaterials. A device can be assessed by examining whether it produces separated release events at the intended times and whether unnecessary exposure is limited between them. These outcomes help determine whether the design can support biological rhythms, disease cycles, or time-dependent treatment needs while potentially improving therapeutic effectiveness and adherence.